http://www.menopause.org/docs/default-source/2015/2015-nams-hormone-therapy-after-age-65.pdf.http://www.menopause.org/docs/default-source/2015/2015-nams-hormone-therapy-after-age-65.pdf
Сметник В. П. От главного редактора. Климактерий, 2011, 2: 3-53.
Сметник В.П., Балан В.Е, Зайдиева Я.З., Майчук Е.Ю, Мычка В.Б. и др. Ведение женщин с сердечно-сосудистым риском в пери- и постменопаузе. Российский кардиологический журнал, 2008, 4: 40-57.
Shufelt CL, Merz CN, Prentice RL et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause, 2014, 21: 260-6.
Nachtigall LE, Nachtigall MJ. The perimeno-pause and vasomotor symptoms. Posgraduate Medicine, A special report, 1990: 5-7.
Raus K, выступление на конференции «Press 2011 - Gynecology and Urology. Phytoneering research and experience summit» (Майорка, 2011).
The North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 2012, 19: 257.
Avis NE, Crawford SL, Greendale G et al. The Study of Women's Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition [published online ahead of print February 16, 2015]. JAMA Intern Med. doi:10.1001/jamain-ternmed.2014.8063..
DOI: 10.1001/jamain-ternmed.2014.8063
Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years [published online ahead of print February 20, 2015]. Menopause.doi: 10.1097/ gme.0000000000000383.
DOI: 10.1097/ gme.0000000000000383
Kaunitz AM, Manson JE. EDITORIAL. Failure to treat menopausal symptoms: a disconnect between clinical practice and scientific data. Menopause, 2015, 22 (7): 000/000. DOI: 10.1097/gme.0000000000000457..
DOI: 10.1097/gme.0000000000000457
Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA, 2011, 306: 1884-1890.
Manson et al. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 2013, 310: 1353-1368.
Stefanick ML. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. JAMA, 2013, 310: 1353-68.
Kaunitz AM. Hormone therapy and breast cancer risk: trumping fear with facts. Menopause, 2006, 13: 160-163.
Courtin A, Communal L, Vilasco M et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogester-one acetate effects in breast cells. Breast Cancer Res Treat, 2012, 131: 49-63.
Courtin A, Communal L, Vilasco M et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogester-one acetate effects in breast cells. Breast Cancer Res Treat, 2012, 131: 49-63.
Smith GC, Wood AM, White IR, Pell JP, Hattie J. Birth weight and the risk of cardiovascular disease in the maternal grandparents. Am J Epidemiol, 2010, 171: 736-44.
de Villiers TJ, Pines A, Panay N et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric, 2013, 16: 316-337.
de Villiers TJ, Gass ML, Haines CJ et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric, 2013, 16: 203-4.
ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol., 2014, 123: 202-216.
Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethin-drone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause, 2005, 12: 741-8.
Archer DF, Schmelter T, Schaefers M, Gerlinger C, Gude K. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17p-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause, 2014, 21(3): 227-35. doi: 10.1097/ GME.0b013e31829c1431..
DOI: 10.1097/ GME.0b013e31829c1431
Smetnik V.P. From the editor in chief. Menopause, 2011 2: 3-53.
Smetnik V.P., Balan V.E., Zaydieva Ya.Z., Maychuk E.Y., Mychka V.B. et al. Management of women with cardiovascular risk in peri- and postmenopausal periods. Rossiyskiy Kardiologicheskiy Zhurnal, 2008, 4: 40-57.